Do FDA Submission, Approval Declines Outside Cancer Signal Future Treatment Gaps?
Executive Summary
Outlining a "fairly substantial decline in the number of non-oncology NMEs approved compared to last year" plus downward trend in applications, US FDA's Jenkins underscores continued "tremendous needs" for primary care products.
You may also be interested in...
NME Mid-Year Report: Approvals Might Near Record With Strong 2nd Half
CDER approved 23 new drugs in the first half of 2017, topping the 22 approved in all 2016; there are at least 18 products in CDER's pipeline with a user fee date this year.
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Sen. Burr asks FDA whether fee revenue should be rebated for not meeting some PDUFA V goals.
Keeping Track: CDER 2016 Novel Approvals Hold At 22 As US FDA Declines Cempra's Solithera
The latest drug development news and highlights from our FDA Performance Tracker.